CN103083501A - Soft capsule preparation for preventing and treating diseases of old people - Google Patents
Soft capsule preparation for preventing and treating diseases of old people Download PDFInfo
- Publication number
- CN103083501A CN103083501A CN2012104501306A CN201210450130A CN103083501A CN 103083501 A CN103083501 A CN 103083501A CN 2012104501306 A CN2012104501306 A CN 2012104501306A CN 201210450130 A CN201210450130 A CN 201210450130A CN 103083501 A CN103083501 A CN 103083501A
- Authority
- CN
- China
- Prior art keywords
- soft capsule
- percent
- preventing
- capsule preparation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a soft capsule preparation for preventing and treating diseases of old people. The preparation comprises the following main and auxiliary raw materials in percentage by weight: 3 to 48 percent of sabal extract, 1 to 20 percent of lycoypene, 0.1 to 0.7 percent of coenzyme Q10, 0.1 to 5 percent of lecithin, 25 to 40 percent of alpha-linolenic acid, and 0.1 to 10 percent of auxiliary materials. The soft capsule preparation relates to a prescription with anti-inflammatory, anti-oxidation, blood cholesterol reduction functions, and the preparation prepared by using the prescription has the functions of inhibiting benign prostatic hyperplasia, delaying senescence, preventing cancer, preventing cardiovascular diseases, preventing senile dementia and the like.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of soft capsule preparation for the control epidemiology.
Background technology
Sabal is herbaceous plant, and it has obvious effect to benign prostate hyperplasia (BPH), and is used in doctor formula, and is widely popular in American-European countries, all can buy in the health food brand shop of many countries.BPH belongs to one of common andropathy.Add up according to clinical medicine: more than 50 years old in the man sickness rate of BPH be about 40% ~ 50%, and in the old man of over-65s the sickness rate of BPH up to 60% ~ 65%.The people that prostate hyperplasia and other prostatosis are suffered from by China has thousands of crowds.The BPH curative of present clinical use mostly is greatly androgen antagonism class Western medicine such as finasteride etc., and the anti-Bears hormonal medicaments of this class of life-time service easily has side effects.Saw Palmetto P.E improves effect due to Western medicine for early stage prostatauxe, its main mechanism of action is that non-competitive inhibition 5 alpha-reductases are active, suppressing testosterone transforms to dihydrotestosterone (DHT), also can suppress dihydrotestosterone is combined with androgen receptor, dwindle prostate volume, improve the subjective and objective symptom of prostatosis.
Lycopene is a kind of fat-soluble unsaturated hydrocarbon, is a kind of of carotenoid, with beta-carotene be isomers.It is generally acknowledged, lycopene reaches the multiple model of action such as impact on GJIC to the quencher of singlet oxygen and removing, blocking nitrosamine formation formation, inhibition cell proliferation, Cell differentiation inducing activity, enhancing immunity, the minimizing DNA damage of free radical, plays the effect of slow down aging, prophylaxis of cancer and cardiovascular disease.In oils and fats, the lycopene bioavailability is higher, and fat is to affect lycopene in one of key factor of intestinal absorption.
Coenzyme Q10 is a kind of material that is similar to vitamin that is dissolvable in water fat, exists in each cell of human body.It is energy-producing vital factor in human body, and it is present in various foods, also can synthesize in tissue.In human body, the total content of coenzyme Q10 is only 500 ~ 1500 milligrams, and reduces with age.The mankind are in the time of 20 years old, and the ability of autonomous synthesizing coenzyme Q 10 reaches Xiang Feng, is maintained until about 50 years old, can descend year by year later on.Nowadays, the developed country such as American-European, Japanese the height of human body coenzyme Q 10 content as weighing one of whether healthy important indicator.The body coenzyme Q 10 mainly concentrates in mitochondrion, can help the myocardial cell produce power, and the state of an illness of heart failure is had the good effect of improving, and can extend the cardiac muscle life-span.Coenzyme Q10 also has remarkable antioxidation, can promote the metabolism of skin cell, improves the coarse situation of scaly dry skin, has all added coenzyme Q10 in a lot of cosmetics of super quality.
Lecithin can promote brain development, memory reinforcing.The choline that lecithin discharges through digestion, generate acetylcholine with the acetyl reaction under the choline acetyltransterase effect, the acetyl choline content increase can promote the cerebral nerve synapse flourishing rapidly, thereby make information transmission speed quickening between neurocyte in brain, can strengthen the brain vigor, can eliminate brain fag, strengthen short term memory power, can prevent senile dementia.In addition, the choline in phospholipid has affinity to fat, and fat is gone out by blood transport by liver with phospholipid form.Phospholipid can improve serum ester matter, removes peroxide, promotes the dissipation of atherosis speckle.
The research discovery, taking alpha-linolenic acid is the effective way of prevention senile dementia, and the symptom of alleviating senile dementia is played positive role.Alpha-linolenic acid is as the parent of omega-3 unsaturated fatty acid. but metabolism produces multiple high activity material under the effect of carbochain extending enzyme and dehydrogenase, and wherein most important have EPA and a DHA.EPA is three to be the precursor substance of prostaglandin.Generate PGE5, PGI3, LTB5, TXA3 isoreactivity material under the effect of lipoxidase and Cycloxygenase, the many biochemical reactions of regulation and control body.DHA (being commonly called as NAOHUANGJIN) is the primary structure material of the tissues such as brain, nerve, retina, it can promote the synthetic of the interior nucleic acid protein of brain and monoamine neurotransmitter, thereby promote the permeability of cerebral nerve film, presynaptic caudacoria, make the nerve information transmission path unimpeded, improve the neural reflex ability.If lack omega-3 unsaturated fatty acid in body, will cause that Human Lipid Metabolism is disorderly, cause the generation of the symptoms such as senile dementia, mental fatigue, visual deterioration, arteriosclerosis.
Above five kinds of materials differ from one another, and act on differently, do not unite temporarily on the market the preparation of use and pertinent literature, patent report.
Summary of the invention
The purpose of this invention is to provide a kind of soft capsule preparation for the control epidemiology, above-mentioned five kinds of materials are united use, disease common in elderly population is had better prevention effect.These diseases comprise prostatic hyperplasia, cancer, atherosclerosis, senile dementia etc.
The present invention is achieved in that a kind of soft capsule preparation for the control epidemiology, the percentage by weight that it is characterized in that each main auxiliary material is: Saw Palmetto P.E 3 ~ 48%, lycopene 1 ~ 20%, coenzyme Q10 0.1 ~ 0.7%, lecithin 0.1 ~ 5%, alpha-linolenic acid 25 ~ 40%, adjuvant 0.1 ~ 10%.
Alpha-linolenic acid of the present invention derives from one or both in Oleum Perillae and Semen Lini oil.
Adjuvant of the present invention is one or more in Cera Flava, mono stearate glyceryl ester, shortening, micropowder silica gel.
The present invention has better prevention effect to disease common in elderly population.These diseases comprise prostatic hyperplasia, cancer, atherosclerosis, senile dementia.
The invention relates to a kind of formula with antiinflammatory, antioxidation, reduction blood cholesterol levels function, the preparation that uses this formula to make has the functions such as Suppress hyperplasia of prostate, slow down aging, prophylaxis of cancer, angiocardiopathy preventing, prevention senile dementia.
The specific embodiment
A kind of soft capsule preparation for the control epidemiology is characterized in that the percentage by weight of each main auxiliary material is: Saw Palmetto P.E 3 ~ 48%, lycopene 1 ~ 20%, coenzyme Q10 0.1 ~ 0.7%, lecithin 0.1 ~ 5%, alpha-linolenic acid 25 ~ 40%, adjuvant 0.1 ~ 10%.Described alpha-linolenic acid derives from one or both in Oleum Perillae and Semen Lini oil.Described adjuvant is one or more in Cera Flava, mono stearate glyceryl ester, shortening, micropowder silica gel.During concrete enforcement, the preparation method of its soft capsule is first with after lycopene, coenzyme Q10, lecithin, alpha-linolenic acid, adjuvant mix homogeneously, then is used for the compacting soft capsule after adding Saw Palmetto P.E to stir.
Further illustrate the present invention below by embodiment, but not as limitation of the present invention.
Embodiment 1
A kind of preparation (double centner) for the control epidemiology forms (kilogram) by weight components: Saw Palmetto P.E 48, lycopene 1, coenzyme Q10 0.5, lecithin 1, Cera Flava 3, Oleum Perillae 46.5;
After the said components mix homogeneously, be pressed into soft capsule, every heavy 600mg of soft capsule content.
Embodiment 2
A kind of preparation (double centner) for the control epidemiology forms (kilogram) by weight components: Saw Palmetto P.E 20, lycopene 20, coenzyme Q10 0.1, lecithin 3, mono stearate glyceryl ester 6, Semen Lini oil 50.9;
After the said components mix homogeneously, be pressed into soft capsule, every heavy 600mg of soft capsule content.
Claims (3)
1. a soft capsule preparation that is used for the control epidemiology, is characterized in that the percentage by weight of each main auxiliary material is: Saw Palmetto P.E 3 ~ 48%, lycopene 1 ~ 20%, coenzyme Q10 0.1 ~ 0.7%, lecithin 0.1 ~ 5%, alpha-linolenic acid 25 ~ 40%, adjuvant 0.1 ~ 10%.
According to claim 1 a kind of for the control epidemiology soft capsule preparation, it is characterized in that: described alpha-linolenic acid derives from one or both in Oleum Perillae and Semen Lini oil.
According to claim 1 a kind of for the control epidemiology soft capsule preparation, it is characterized in that: described adjuvant is one or more in Cera Flava, mono stearate glyceryl ester, shortening, micropowder silica gel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104501306A CN103083501A (en) | 2012-11-13 | 2012-11-13 | Soft capsule preparation for preventing and treating diseases of old people |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104501306A CN103083501A (en) | 2012-11-13 | 2012-11-13 | Soft capsule preparation for preventing and treating diseases of old people |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103083501A true CN103083501A (en) | 2013-05-08 |
Family
ID=48196980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104501306A Pending CN103083501A (en) | 2012-11-13 | 2012-11-13 | Soft capsule preparation for preventing and treating diseases of old people |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103083501A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103238846A (en) * | 2013-05-31 | 2013-08-14 | 烟台燕园科玛生物技术开发有限公司 | Alpha-linolenic acid soft capsule |
| CN103734696A (en) * | 2013-11-21 | 2014-04-23 | 荣成百合生物技术有限公司 | Softgel for improving immunity and protecting internal organs, and preparation method thereof |
| CN106902150A (en) * | 2017-03-16 | 2017-06-30 | 桦南仙紫食品科技有限公司 | Co-Q10 purple perilla soft capsule prescription and preparation method |
| CN114832002A (en) * | 2022-05-17 | 2022-08-02 | 新乡医学院 | Bioactive composition for preventing and/or treating Alzheimer disease and application thereof |
| EP3958973A4 (en) * | 2019-04-26 | 2023-06-07 | Cytosolve, Inc. | Compositions for improving brain health and memory |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634075A (en) * | 2004-10-28 | 2005-07-06 | 昆明翔昊科技有限公司 | Lycopene and coenzyme Q#-[10] containing formulation and its manufacturing method |
| CN201088722Y (en) * | 2007-03-29 | 2008-07-23 | 东莞劲芳生物医药孵化器有限公司 | Saw palmetto fruit extract soft capsule |
| CN102018823A (en) * | 2009-09-17 | 2011-04-20 | 上海泰佳生物科技有限公司 | Composite preparation containing phospholipid, alpha-linolenic acid, gamma-linolenic acid and tomato extract |
| CN102754829A (en) * | 2012-07-03 | 2012-10-31 | 广东仙乐制药有限公司 | Healthcare composition containing coenzyme Q10, capsule preparation and preparation method |
-
2012
- 2012-11-13 CN CN2012104501306A patent/CN103083501A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634075A (en) * | 2004-10-28 | 2005-07-06 | 昆明翔昊科技有限公司 | Lycopene and coenzyme Q#-[10] containing formulation and its manufacturing method |
| CN201088722Y (en) * | 2007-03-29 | 2008-07-23 | 东莞劲芳生物医药孵化器有限公司 | Saw palmetto fruit extract soft capsule |
| CN102018823A (en) * | 2009-09-17 | 2011-04-20 | 上海泰佳生物科技有限公司 | Composite preparation containing phospholipid, alpha-linolenic acid, gamma-linolenic acid and tomato extract |
| CN102754829A (en) * | 2012-07-03 | 2012-10-31 | 广东仙乐制药有限公司 | Healthcare composition containing coenzyme Q10, capsule preparation and preparation method |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103238846A (en) * | 2013-05-31 | 2013-08-14 | 烟台燕园科玛生物技术开发有限公司 | Alpha-linolenic acid soft capsule |
| CN103734696A (en) * | 2013-11-21 | 2014-04-23 | 荣成百合生物技术有限公司 | Softgel for improving immunity and protecting internal organs, and preparation method thereof |
| CN103734696B (en) * | 2013-11-21 | 2016-01-27 | 威海百合生物技术股份有限公司 | A kind of soft capsule and preparation method thereof improving immunity, protection internal organs |
| CN106902150A (en) * | 2017-03-16 | 2017-06-30 | 桦南仙紫食品科技有限公司 | Co-Q10 purple perilla soft capsule prescription and preparation method |
| EP3958973A4 (en) * | 2019-04-26 | 2023-06-07 | Cytosolve, Inc. | Compositions for improving brain health and memory |
| CN114832002A (en) * | 2022-05-17 | 2022-08-02 | 新乡医学院 | Bioactive composition for preventing and/or treating Alzheimer disease and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8772270B2 (en) | Treatment methods requiring phyto-ingredients | |
| Berger et al. | Plant sterols: factors affecting their efficacy and safety as functional food ingredients | |
| JP2020127400A (en) | Lipid-containing compositions and methods of use thereof | |
| Harris et al. | Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids | |
| CN103083501A (en) | Soft capsule preparation for preventing and treating diseases of old people | |
| Kummerow et al. | Trans fatty acids in hydrogenated fat inhibited the synthesis of the polyunsaturated fatty acids in the phospholipid of arterial cells | |
| JP2016504999A (en) | Eicosapentaenoic acid (EPA) formulation | |
| US8507466B2 (en) | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy | |
| CN105918505A (en) | Blend oil rich in alpha-linolenic acid and capable of protecting cardiovascular system | |
| JP2009537582A (en) | New uses for organic compounds | |
| Mauriz et al. | Effects of a low-fat diet with antioxidant supplementation on biochemical markers of multiple sclerosis long-term care residents | |
| Ahire et al. | Role of omega-3 fatty acids in different neurodegenerative disorders | |
| JP3746270B2 (en) | Anticholesterolemia cooking oil | |
| Hoi et al. | Sorghum distillers dried grain lipid extract increases cholesterol excretion and decreases plasma and liver cholesterol concentration in hamsters | |
| Banning | The role of omega-3-fatty acids in the prevention of cardiac events | |
| AU2006300629B2 (en) | Agent for inhibiting Visceral fat accumulation | |
| CN101194913A (en) | Natural seal oil compression biological preparation for treating hyperlipidemia and technique of preparing the same | |
| CN102499364B (en) | Soft capsule health-care food capable of delaying senility and resisting radiation | |
| CN101305754A (en) | Health-care edible oil for adjusting blood fat and its preparation method | |
| Leyva et al. | Medicinal use of hempseeds (Cannabis sativa L.): effects on platelet aggregation | |
| Malik et al. | Dietary Lipids and Health | |
| Awan et al. | Effect of date fruit supplemented diet on serum lipidemic and oxidative stress biomarkers in rodent experimental modelling | |
| Jarreau et al. | Should we start prescribing omega-3 polyunsaturated fatty acids in chronic heart failure? | |
| K Mishra et al. | Chemistry and Pharmacology of Bioactive Molecule-Coenzyme Q10: A Brief Note | |
| Saidaiah et al. | A comprehensive review of Omega-3 fatty acids: Sources, industrial applications, and health benefits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130508 |